Introduction

While early stage colon cancer has a 5-year survival rate of 60%,1 metastatic colon cancer has a 5-year survival rate of 12.9%.1 The low 5-year survival rate for metastatic colon cancer is due to many factors, including inherent chemoresistance and acquired resistance to treatment.2 The prognosis for pancreatic cancer is even more grim: the 5-year survival rate for early stage pancreatic cancer is 27.1%,1 while metastatic pancreatic cancer has a 5-year survival rate of 2.4%.1 The inherent difficulty in treating pancreatic cancer is related to late diagnosis and the resistance of pancreatic cancer cells to chemotherapy.3 These dismal prognoses underscore an important need for more effective therapeutics and for identifying novel therapeutic targets.

While standard cancer chemotherapies have a broad-based mechanism of action, novel cancer therapies take a more focused approach by targeting proteins that are unique to cancer cells. Thus, targeted therapies are much better tolerated than standard chemotherapy, because patients do not experience the common symptoms that are due to the off-target effects of standard chemotherapy, such as hair loss and immune suppression. Some examples of targeted therapies used in the treatment of colorectal cancer and pancreatic cancer include Avastin and Erlotinib. Avastin is a monoclonal antibody directed against vascular endothelial growth factor (VEGF), thereby inhibiting angiogenesis, and is used in the treatment of colorectal cancer.2 Erlotinib is a small-molecule inhibitor of epidermal growth factor receptor (EGFR), thereby inhibiting cell survival and proliferation, and is used in the treatment of pancreatic cancer.3 While the combination of standard chemotherapy with targeted therapy improves survival compared with standard therapy alone, resistance often develops, which highlights the need for novel drug targets and targeted therapies.2

Prostate apoptosis response protein 4 (Par-4) is a tumor-suppressor gene that has therapeutic potential as a targeted therapy. Par-4 was originally found to be upregulated in prostate cancer cells undergoing cell death.4 Par-4 is a tumor-suppressor that is activated by PKA and regulates apoptosis in a cell-type-specific manner.5 Par-4 overexpression is sufficient to induce apoptosis in vitro and in vivo in multiple types of cancer, such as breast cancer, lung cancer, and melanoma.6,7 In other cell types, such as Jurkat T lymphocytes,8 Par-4 increases cell susceptibility to pro-apoptotic stimuli. In colon cancer cells, Par-4 overexpression sensitizes cells to apoptosis in response to the chemotherapeutic agent, 5-fluorouracil,9 and Akt inhibitor, ISC-4.10 In pancreatic cancer cells, treatment with inhibitors of NF-κB and Bcl-2 induce Par-4 expression, which in turn sensitizes cells to chemotherapeutic-induced apoptosis.11,12

Par-4 is able to regulate apoptosis via activation of both the extrinsic13 and intrinsic pathways of apoptosis.8,14–17
Par-4 overexpression can induce apoptosis partly by translocating the death receptors Fas \[^{13,16}\] and DR 5, \[^{19}\] and the death ligand, FasL, \[^{13}\] to the cell membrane; this, in turn, results in the cleavage of caspase 8 \[^{13,19}\] and engagement of the extrinsic pathway of apoptosis. Par-4 overexpression also downregulates the anti-apoptotic protein, Bcl\[^{-2}\] \[^{8,14-17}\] which in turn increases mitochondrial permeability and the release of cytochrome c, caspase-9 cleavage, and engagement of the intrinsic pathway.

While most Par-4 studies have focused on characterizing the function of Par-4, its regulation is a relatively understudied area. Par-4 has been shown to be upregulated in response to treatment with various natural products and small-molecules. \[^{20-22}\] Recently, Par-4 has been shown to be transcriptionally upregulated by FOXO3a in response to treatment with Withaferin A. \[^{23}\] Ubiquitination of target proteins by E3 ligases followed by proteasomal degradation is a common mechanism for downregulating protein levels and activity. The ubiquitination of Par-4 by FBXO45 and its subsequent proteasomal degradation has been demonstrated to regulate cancer cell survival. \[^{24}\] TRIM21, an E3 ligase, was first discovered as an autoantigen associated with autoimmune diseases, such as systemic lupus. Like other E3 ligases, TRIM21 functions by ubiquitination of target substrates. For example, TRIM21 regulates innate immune signaling through ubiquitination of DDX41, an intracellular DNA sensor, thereby inhibiting the innate immune response to intracellular dsDNA. \[^{25}\] In addition, multiple members of the IRF family of proteins, which is a family of transcription factors that are activated and act downstream of toll-like receptors, are substrates of TRIM21. \[^{26,27}\] Thus, TRIM21 negatively regulates the innate immune response to foreign pathogens.

While most studies have examined the role of TRIM21 in regulating innate immune signaling, some studies have implicated TRIM21 in the regulation of other cellular processes. For example, TRIM21 has been shown to positively regulate apoptosis via ubiquitination of apoptosis inhibitors, such as Bcl\[^{-2}\] and c-FLIP, leading to their degradation. \[^{28,29}\] Furthermore, TRIM21 has been shown to be a negative regulator of B-cell proliferation. \[^{30}\] The above findings suggest a possible tumor-suppressive role of TRIM21. In line with this, 2 recent studies have shown that reduced TRIM21 expression is correlated with poor prognosis in hepatocellular carcinoma and diffuse large B-cell lymphoma. \[^{31,32}\]

Table 1. HCT-116, HT-29, and KM12C cells were grown and either transfected with Par-4 expression plasmid or control plasmid for 48 hrs. Par-4 was immunoprecipitated from whole cell lysates using anti-Par-4 antibody and protein G magnetic beads. An in-solution trypsin digestion was performed on the eluted proteins, and the digests were sent for mass spectrometry analysis. A representative list of the most abundant proteins identified in the digest reveals TRIM21 as a potential novel interacting partner of Par-4.

| Accession | Name | IP α HA |
|-----------|------|--------|
| gi | 62414289 | vimentin [Homo sapiens] |
| gi | 58331171 | T-complex protein 1 subunit zeta isoform b [Homo sapiens] |
| gi | 4502643 | T-complex protein 1 subunit zeta isoform a [Homo sapiens] |
| gi | 31542947 | 60 kDa heat shock protein, mitochondrial [Homo sapiens] |
| RRGGGG | 62422577 | REVERSED neurobeachin isoform 1 [Homo sapiens] |

| Accession | Name | IP α Par-4 |
|-----------|------|---------|
| gi | 55769533 | PRKC apoptosis WT1 regulator protein [Homo sapiens] |
| gi | 15208660 | E3 ubiquitin-protein ligase TRIM21 [Homo sapiens] |
| gi | 4826998 | splicing factor, proline- and glutamine-rich [Homo sapiens] |
| cont | 000394 | Trypa5 |
| cont | 000394 | Trypa5/Promega trypsin artifact 5 K to R mods (22391, 2914)(1987, 2003). |
| gi | 4506583 | replication protein A 70 kDa DNA-binding subunit [Homo sapiens] |

Identifying novel regulators of Par-4 represents a potential avenue for identifying new drug targets for colon and pancreatic cancer. In this study, we identify TRIM21 as a novel interaction partner of Par-4 in colon cancer cells. Furthermore, we show that TRIM21 can regulate Par-4 levels in response to cisplatin in both pancreatic cancer and colon cancer cell lines. Finally, we show that TRIM21 may represent a potentially novel therapeutic target and biomarker.

**Results**

**TRIM21 is a novel interacting partner of Par-4**

In order to discover new regulators of Par-4, we sought to identify novel binding partners of Par-4. To identify novel binding partners of Par-4, we performed an immunoprecipitation of Par-4 from HCT-116, HT-29, and KM12C colon cancer whole cell lysates that had been transiently transfected with Par-4 plasmid. The purpose of the transfection was to increase the signal. Proteins that co-precipitated with Par-4 were analyzed by mass spectrometry for identification. TRIM21 was identified as an interacting protein in all 3 cell lines tested. A representative list of the top identified proteins in the pull-down and the negative control pull-down is shown in Table 1. To validate the mass-spectrometry result and to confirm that the interaction between Par-4 and TRIM21 was not an artifact of the ectopic Par-4 expression, reciprocal co-immunoprecipitations were performed with endogenous Par-4 in HCT-116, HT-29, and KM12C whole cell lysates. As can be seen in Fig. 1A–C, Par-4 and TRIM21 interact endogenously in colorectal cancer cells.

**TRIM21 interacts with Par-4 through its PRY-SPRY domain**

Next, we sought to characterize the Par-4/TRIM21 interaction. Specifically, we wanted to identify which domain of TRIM21 is responsible for mediating its interaction with Par-4. TRIM21 is an E3 ligase that is part of the Tripartite motif (TRIM) family. TRIM family members contain a RING finger domain, a B-box domain, and a coiled-coil domain. TRIM21 is unique in that it also contains a C-terminal PRY-SPRY domain, which is a protein-protein interaction domain. \[^{33}\] A schematic of TRIM21 can be seen in Fig. 2A.

To determine which domain of TRIM21 mediates its interaction with Par-4, we obtained 3 TRIM21 constructs: full-
length, exon 1 deletion, and exon 6 deletion. The exon 1 deletion does not contain the RING domain nor the B-box domain. These domains are responsible for the E3 ligase activity of TRIM21. The exon 6 deletion does not contain the PRY-SPRY domain. A schematic of these constructs can also be seen in Fig. 2A. To test which domain of TRIM21 is responsible for its interaction with Par-4, we co-transfected HCT-116 cells with combinations of the Par-4 plasmid and each of the 3 TRIM21 constructs. We then performed a co-immunoprecipitation against Par-4, and probed for the presence of TRIM21 by Western Blotting (Fig. 2B). The
results show that truncated constructs that contain the PRY-SPRY domain bind to Par-4. However, when the exon containing this motif is deleted, binding is absent, implicating the domain with PRY-SPRY as essential for binding.

**TRIM21 is not sufficient to downregulate Par-4 levels**

Given that TRIM21 is an E3 ligase and interacts with Par-4, we hypothesized that TRIM21 may downregulate Par-4 protein levels via ubiquitination and subsequent proteasomal degradation. The endogenous expression patterns of Par-4 and TRIM21 across a panel of colorectal cancer cell lines appears to show an inverse relationship (Fig. 3A). This inverse relationship suggests that TRIM21 could downregulate Par-4 levels. To test this hypothesis, we ectopically expressed the 3 TRIM21 constructs in SW480 cells by transient transfection, and probed for the expression of Par-4 by Western blotting. The results demonstrate that TRIM21 overexpression is not sufficient to downregulate Par-4 levels (Fig. 3B). These results were corroborated by repeating the experiment using HCT-116 cells (data not shown). This conclusion is further supported by the observation that ectopic TRIM21 expression and TRIM21 knock-down do not regulate the stabilization of Par-4.24

Ectopic expression of TRIM21 downregulates Par-4 in the presence of cisplatin

Given that TRIM21 was not sufficient to downregulate Par-4 levels, we hypothesized that TRIM21 may regulate Par-4 levels in response to a stimulus. Cisplatin (CDDP) is one such stimulus that has been shown to affect Par-4 activity via promoting its cleavage by caspase 3.34 Furthermore, Par-4 downregulation has been demonstrated to induce cisplatin resistance in pancreatic cancer cells via a PI3K/Akt-dependent EMT pathway.35

![Figure 3.](image_url)

**Cisplatin downregulates Par-4 in both the cytoplasmic and nuclear compartments**

To determine an intracellular location of the Par-4 downregulation in response to cisplatin, we transfected HCT-116 cells with...
or without TRIM21 and treated with 3.75 μg/ml of cisplatin or carrier, then performed a nuclear-cytoplasmic fractionation to determine whether the Par-4 downregulation was localized to a specific subcellular compartment. Par-4 protein levels were examined by Western blotting. As can be seen in Fig. 6, the Par-4 downregulation occurs in both the cytoplasmic and nuclear compartments, with the downregulation being slightly more pronounced in the nuclear compartment. Lamin A/B and β-tubulin were probed to confirm the integrity of the subcellular fractionation and to ensure that there was no cross-contamination between compartments during the fractionation.

**Cisplatin downregulates Par-4 in pancreatic cancer cells**

Given that Par-4 was downregulated in response to cisplatin in the presence of overexpressed TRIM21 in colon cancer cells, we wanted to examine whether we could extend this observation to a different type of cancer. To test that hypothesis, we transfected AsPc-1, BxPc-3, and MiaPaca-2 cells, which are all pancreatic cancer cell lines, with empty vector (control) or with TRIM21 for 48 hrs, and treated the cells with increasing doses of cisplatin for 24 hours. We probed whole cell lysates for Par-4 expression via Western blotting. We observed an enhanced dose-dependent downregulation of Par-4 in response to cisplatin treatment in TRIM21-transfected cells compared with control cells (Fig. 7A–C).

**TRIM21 is a potential therapeutic target in colon and pancreatic cancer**

Given the effect of TRIM21 on Par-4 in response to cisplatin, we hypothesized that TRIM21 could contribute to cisplatin resistance. To address this question, we performed an MTT viability assay on HCT-116 cells that had either been transfected with TRIM21 plasmid or control plasmid, followed by treatment with increasing concentrations of cisplatin. The data show that TRIM21 decreases the sensitivity of HCT-116 cells to cisplatin (Fig. 8A). Specifically, HCT-116 cells had statistically significant increases in viability at cisplatin doses between 0.5–10 μg/ml, with a right shift in IC50 from approximately 5 μg/ml to 10 μg/ml between the control and TRIM21 transfected cells, respectively. Likewise, we performed an analogous experiment in Panc-1 cells, a pancreatic cancer cell line. To our surprise, ectopic TRIM21 expression in Panc-1 cells had no effect on Panc-1 cell viability in response to cisplatin (data not shown). Despite that finding, we show in Fig. 8B that ectopic Par-4 expression sensitizes Panc-1 cells to cisplatin-induced apoptosis as indicated by PARP cleavage, specifically at the 15
and 30 μg/ml doses. PARP cleavage was examined by Western blotting and the percentage of the cleavage product was determined using densitometry. Densitometric analysis revealed that Par-4 overexpression increased the levels of apoptosis in Panc-1 cells by 2- to 3-fold relative to the control transfected cells at the 15 and 30 μg/ml doses of cisplatin (Fig. 8B).

Given the effects of TRIM21 on Par-4, and in light of the recent literature suggesting that TRIM21 is a favorable prognostic marker in cohorts of hepatocellular carcinoma and diffuse large B-cell lymphoma patients, we asked whether TRIM21 has prognostic significance in either colorectal or pancreatic cancer. To answer this question, we downloaded data from the TCGA database, stratified by TRIM21 expression: TRIM21 high (Z-score > 2), TRIM21 low (Z-score < −2), and TRIM21 intermediate (−2 < Z-score < 2). Then, we plotted Kaplan Meier survival curves of these 3 TRIM21 expression groups in the colorectal and pancreatic cancer cohorts. There was no statistically significant difference in overall survival or disease-free survival in the colorectal cancer cohort between the 3 TRIM21 expression groups (data not shown). In contrast, in pancreatic cancer there was a dramatic increase in overall survival in the TRIM21 low cohort relative to the intermediate and high cohorts (p = 0.0043), as can be seen in Fig. 8C. Though the difference in overall survival was not significantly different between the TRIM21 high and intermediate groups (p = 0.2121), the TRIM21 high group seems to be trending toward reduced overall survival relative to the intermediate group (Fig. 8C). Likewise, the trends in disease-free survival follow the same patterns as the trends in overall survival in the pancreatic cancer cohort. Specifically, low TRIM21 expression correlates with increased disease-free survival, whereas high TRIM21 expression correlates with reduced disease-free survival relative to the TRIM21 intermediate cohort, as can be seen in Fig. 8D. In the disease-free survival curve, the TRIM21 high, intermediate, and low expression groups were all significantly different from each other (p < 0.01).

Discussion

In this study, we identified TRIM21 as a novel interaction partner of Par-4, and demonstrate that they interact endogenously. We show that the binding occurs through the PRY-SPRY domain of TRIM21. Though TRIM21 is not sufficient to downregulate Par-4 levels, we show that in response to cisplatin TRIM21 downregulates Par-4 in a dose- and proteasome-dependent manner in both the nucleus and cytoplasm. Furthermore, we show that TRIM21 can increase the resistance of cancer cells to cisplatin and that by overexpressing Par-4, cancer cells can be sensitized to cisplatin-induced apoptosis. Finally, we demonstrate that TRIM21 expression can predict overall and disease-free survival in a cohort of pancreatic cancer patients.
Par-4 is an important tumor-suppressor whose expression is downregulated in several cancers. In addition, its ability to selectively induce and sensitize cancer cells toward apoptosis underscores the tremendous therapeutic potential of Par-4. Therefore, understanding the mechanisms of Par-4 regulation is an important, yet understudied, area of research, and our work represents an advance in our understanding of how Par-4 is regulated. Chen et al. showed that Par-4 levels could be post-translationally regulated by the proteasome through targeting by Fbxo45. Brasseur et al. showed that cleaved Par-4 is also regulated by the proteasome. We now report a stimulus-dependent regulation of Par-4 by the proteasome. That stimulus is cisplatin. This observation is significant, since cisplatin and its analogs are used in the treatment of colon and pancreatic cancer. Additionally, the subcellular localization of Par-4 is important, because its nuclear localization is correlated with its apoptotic function. Thus, our finding that its downregulation is present in the nucleus, along with in the cytoplasm, is also significant.

By identifying a novel mechanism of regulation of Par-4, we in turn discovered a potentially new therapeutic target: TRIM21. This is especially important for pancreatic cancer, where most patients ultimately succumb to their disease, and are therefore in need of novel, effective therapies. Here, we show that low TRIM21 levels correlate with prolonged overall and disease-free survival in pancreatic cancer patients. Conversely, we showed that high TRIM21 levels correlate with lower disease-free survival. This intriguing finding is the opposite of the protective effects of TRIM21 in hepatocellular carcinoma and diffuse large B-cell lymphoma. This illustrates the complexity of disease biology, and the prognostic differences of TRIM21 may reflect differences in downstream TRIM21 targets, such as Par-4, in different types of cancer. Further study of the role of TRIM21 in pancreatic cancer is needed.

Our work has given rise to the concept that, in the presence of high TRIM21 levels, cisplatin downregulates Par-4, at least partially through the proteasome. Other work has been done on the relationship between cisplatin and Par-4. For example, cisplatin has been shown to activate Par-4 via cleavage by caspase 3. In this instance, the cleaved Par-4 had more apoptotic activity and a greater nuclear localization than full-length Par-4. In another study, Par-4 downregulation was shown to confer resistance to cisplatin through the PI3K/Akt pathway. In this example, Par-4 overexpression reversed the resistance phenotype. Our work adds to the complex relationship between cisplatin and Par-4, and gives rise to interesting questions. For example, understanding the mechanisms immediately downstream of cisplatin-induced DNA damage that determine whether Par-4 is cleaved to a more active form versus downregulated would be an important area of study. Finding ways to switch from cisplatin-induced Par4 downregulation to cisplatin-induced Par-4 cleavage could be beneficial. In addition, it would be interesting to examine whether Par-4 downregulation occurs solely in response to the DNA-crosslinking that occurs during cisplatin treatment, or whether this response

Figure 8. TRIM21 is a potential therapeutic target in colon and pancreatic cancer. (a) HCT-116 cells were either transfected with a plasmid encoding TRIM21 or control plasmid for 48 hrs, and then treated with increasing doses of cisplatin for 24 hrs, and viability was assessed by MTT assay. Viability is plotted as a percentage of control samples. Asterisks indicate statistically significant differences in viability between TRIM21 and control transfected cells. (b) Panc-1 cells were either transfected with a plasmid encoding Par-4 or control plasmid for 48 hrs, and then treated with increasing doses of cisplatin. Cisplatin doses are shown in units of µg/ml. Levels of PARP and Par-4 levels were examined by Western blotting. Percentage of cleaved PARP, as determined by densitometric analysis, is shown below the blots. Kaplan-Meier survival curves showing overall survival, Fig. 8c, and progression-free survival, Fig. 8d, of a cohort of pancreatic cancer patients stratified by TRIM21 mRNA expression levels. Data was obtained.
extends to other types of DNA damage, such as double-strand breaks.

In conclusion, our data show that TRIM21 is a novel interaction partner of Par-4 and a novel regulator of Par-4 in response to cisplatin treatment. Our model suggests that TRIM21 may influence sensitivity of cancer cells to cisplatin. Targeting TRIM21 may potentially be a way to enhance the effectiveness of cisplatin treatment, and may represent an important therapeutic target, especially in pancreatic cancer.

**Materials/methods**

**Cell culture, transfection, plasmids, reagents, and antibodies**

HCT-116, SW480, and HT-29 colorectal cancer cells were obtained from ATCC and maintained in RPMI (Cellgro, Manassas, VA) + 10% fetal bovine serum (FBS). Panc-1 cells were a kind gift from Dr. Arun Sharma and were maintained in DMEM (Cellgro, Manassas, VA) + 10% fetal bovine serum (FBS). The anti-TRIM21, anti-Lamin A/C, and anti-Par-4 antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-actin and anti-β-tubulin antibodies were obtained from Sigma-Aldrich (Saint Louis, MO). The anti-PARP antibody was obtained from Cell-Signaling (Danvers, MA). Cisplatin was obtained from Acros Organics (Thermo Fisher, Waltham, MA). MG132 was obtained from Fisher (Thermo Fisher, Waltham, MA).

**Western blot analyses**

To examine changes in cell expression, cells were washed twice with PBS and were lysed into lysis buffer (50 mM HEPES, 100 mM NaCl, 10 mM EDTA, 0.5% NP40, 10% glycerol, supplemented with 0.0001% Tween20, 0.1 mM PMSF, 0.1 mM NaVO4, 0.5 mM NaF, 5 μg/ml leupeptin, 0.1 mM DTT). The proteins were quantified according to the BCA Assay (Pierce, Rockford, IL) and loaded equally onto 10% SDS-polyacrylamide gels. Proteins were electrophoresed at 150 V and transferred to nitrocellulose membranes using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, Hercules, CA). Membranes were blocked with 5% non-fat dry milk for 1 h and incubated with primary antibody overnight. The blots were washed 3X in TBS with 0.1% Tween20 and incubated for 1 h in appropriate HRP-conjugated secondary antibodies (Amersham, Piscataway, NJ). Blots were washed 3X and chemiluminescent detection was performed using Amersham ECL Prime Western Blotting Detection Reagent (Thermo Scientific Inc., Rockford, IL). The blots were either exposed to autoradiography film (GE Healthcare Life Sciences, Pittsburgh, PA) and scanned or imaged using the Molecular Imager Gel Doc XR System (Bio-Rad, Hercules, CA).

**Co-IP/Mass-Spec**

To identify novel binding partners of Par-4, HCT-116, HT-29, and SW480 cells were cultured in 2 10-cm dishes and transfected with 5 μg of Par-4 plasmid per dish using SignaGen PolyJet transfection reagent, according to the manufacturer’s instructions. After 48 hours of transfection, cells were lysed in lysis buffer (50 mM HEPES, 100 mM NaCl, 10 mM EDTA, 0.5% NP40, 10% glycerol, supplemented with 0.0001% Tween20, 0.1 mM PMSF, 0.1 mM NaVO4, 0.5 mM NaF, 5 μg/ml leupeptin, 0.1 mM DTT), and the total protein concentration was determined as above.

To perform the co-immunoprecipitation, approximately 3,000 μg of total protein from the lysate was mixed with 2 μg of anti-Par-4 antibody. As a negative control, the same amount of total protein from the lysate was mixed with anti-HA antibody. The antibody-lysate mixtures were allowed to mix overnight at 4°C. The next day the antibody-antigen complexes were pulled down using Dynabeads Protein G (Thermo Fisher Scientific, Leesport, PA) and washed with lysis buffer, according to the manufacturer’s instructions. Proteins are eluted from the beads by boiling at 100°C for 10 mins in digestion buffer (6 M urea, 50 mM Tris-HCl, pH = 8.0). Samples are then cooled on ice and eluate removed from beads.

To perform the in-solution digestion, 5 μl of 200 mM DTT/50 mM Tris-HCl/pH = 8.0 was added to solution, mixed, and allowed to incubate for 1 hr at room temperature. After 1 hr, 20 μl of 200 mM Iodoacetamide/50 mM Tris-HCl/pH = 8.0 is added, mixed, and allowed to incubate at room temperature in the dark for 1 hr. After 1 hr, 775 μl of 50 mM Tris-HCl/1 mM CaCl2/pH = 7.6. 2 microliters of trypsin (0.2 μg/ml) is added, mixed, and allowed to incubate at 37°C overnight. Formic acid is added to bring pH down to 3–4. Solutions are snap frozen in liquid nitrogen and spun to dryness under vacuum. Residue is resuspended in milliQ water, snap frozen in liquid nitrogen, and dried using a speed vac. This process is repeated 2 more times. The final residue is submitted for protein identification via MALDI-TOF mass spectrometry. Proteins are identified from mass spectra using Paragon Algorithm.

**MTT assay**

To examine changes in cell viability, cells were seeded at a density of 6 x 10^4 cells/well in a 96-well culture plate. After 24 hours, the cells were transfected with the appropriate plasmid. Twenty-four hours post-transfection, the medium was replaced with medium containing different concentrations of cisplatin. Twenty-four hours post-cisplatin treatment, MTT reagent was added (Calbiochem) and the cells were incubated for 3.5 hrs at 37°C. After incubation, the media was aspirated off, crystals were dissolved in MTT solvent (4 mM HCl, 0.1% Nonidet P-40, in isopropanol), and viability was assessed by measuring the absorbance at 570 nm with 630 nm absorbance as the reference. Percent viability is expressed as the absorbance normalized to the DMSO control.
**Immunofluorescence**

Cells are grown to approximately 50% confluence on 22 × 22 mm coverslips (#1.5). Media is removed and cells are washed with PBS, followed by fixation with 4% paraformaldehyde in PBS for 15 mins at room temperature. Cells are washed in PBS, then permeabilized 3 × 5 mins with 0.1% Triton X-100 in PBS. Cells are washed with PBS, then blocked with 10% BSA in PBS for 1 hr at room temperature. After one hour, the cells are washed with PBS, a mixture of anti-Par-4 antibody (1:50) and anti-TRIM21 antibody (1:50) in 4% BSA/PBS for 2 hours at room temperature. After the incubation in primary antibody, the cells are washed 4X with PBS for 10 mins each at room temperature with gentle shaking. After washing, the cells are then incubated in a mixture of secondary antibody in 4% BSA/PBS; anti-rabbit FITC (1:100) and anti-mouse Ro (1:100). The secondary antibody incubation is performed in the dark for 2 hours at room temperature. After incubation in secondary antibody, the cells are washed 4X with PBS for 10 mins each at room temperature with gentle shaking. After washing, the cells are incubated with DAPI (0.5 μg/ml in PBS) for 5 mins at room temperature in the dark. After incubation with DAPI, the cells are washed 4X with PBS for 10 mins each at room temperature with gentle shaking. Finally, the coverslips are mounted on glass slides using ProLong Diamond Antifade mountant (Thermo Fisher, Leesport, PA). Slides are imaged using DeltaVision Elite Inverted Microscope. Six random fields are imaged to ensure representativeness.

**Nuclear-cytoplasmic fractionation**

To perform the nuclear-cytoplasmic fractionation, the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Fisher, Leesport, PA) was used, and the manufacturer’s instructions were followed. The resultant extracts were quantified and loaded equally onto a 10% acrylamide gel, and proteins probed by Western blotting.

**Statistical analyses**

The statistical analyses were performed using GraphPad Prism software, version 6.04 (GraphPad Software, Inc., San Diego, CA, USA). All plots were created using GraphPad Prism. All experiments were repeated 3 times with representative experiments shown in the results. For the MTT assay, 2-way ANOVA was used to determine differences between transfectants and controls, using the Sidak correction to correct for multiple comparisons. For the Kaplan-Meier survival curves, the log-rank test was used to determine differences between groups. The pancreatic cancer TCGA data was accessed and downloaded from www.cbioportal.org. TRIM21 high expression was considered to be those that had a Z-score greater than 2. TRIM21 low expression was considered to be those than had a Z-score lower than −2. Patients with intermediate TRIM21 expression had Z-scores between +/− 2. Densitometric analysis was performed using ImageJ. The threshold for statistical significance is P < 0.05.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

The Penn State Hershey Imaging Core is acknowledged for their help in obtaining images.

**Funding**

This work was funded by start-up funds granted to Rosalyn B. Irby.

**References**

1. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance, Epidemiology, and End Results (SEER) Program. National Cancer Institute.

2. Pai SG, Fularia J. Novel therapeutic agents in the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8:99-104; PMID:26798440; http://dx.doi.org/10.4251/wjgo.v8.i11.99

3. Kourie HR, Gharios J, Elkarak F, Antoun J, Ghosn M. Is metastatic pancreatic cancer an untargetable malignancy? World J Gastrointest Oncol 2016; 8:297-304; PMID:26989465; http://dx.doi.org/10.4251/wjgo.v8.i3.297

4. Sells SF, Wood DP Jr., Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, Humphreys S, Rangnekar VM. Quantitation of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 1994; 5:457-66; PMID:8043520

5. Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 2005; 25:1146-61; PMID:15657440; http://dx.doi.org/10.1128/MCB.25.3.1146-1161.2005

6. Irby RB, Kline CL. Par-4 as a potential target for cancer therapy. Exp Opin Therap Targets 2013; 1:77-87; PMID:23062118; http://dx.doi.org/10.1517/14728222.2013.731047

7. Lucas T, Pratscher B, Krishnan S, Fink D, Gunsberg P, Wolschek M, Wacheck V, Muster T, Romirer I, Wolff K, et al. Differential expression levels of Par-4 in melanoma. Melanoma Res 2001; 11:379-83; PMID:11479426; http://dx.doi.org/10.1097/00008390-200108000-00008

8. Roehrer S, Chow KU, Beske F, Kukoc-Zivoinov N, Puccetti E, Rutherford M, Baum C, Rangnekar VM, Hoelder D, Mitrou PS, et al. In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res 2002; 62:1768-75; PMID:11912153

9. Kline CL, Shannagavelandy SS, Kester M, Irby RB. Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biol Ther 2009; 8:1831-7; PMID:19729995; http://dx.doi.org/10.1177/1535759709342010

10. Sharma AK, Kline CL, Berg A, Amin S, Irby RB. The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model. Clin Cancer Res 2011; 17:4474-83; PMID:21555373; http://dx.doi.org/10.1158/1078-0432.CCR-10-2370

11. Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, Sarkar FH. Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3’ diindolylmethane (DIM). Pharm Res 2008; 25:2117-24; PMID:18427961; http://dx.doi.org/10.1007/s11095-008-9581-8

12. Azmi AS, Wang Z, Burikhanov R, Rangnekar VM, Wang G, Chen J, Wang S, Sarkar FH, Mohammad RM. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther 2008; 7:2884-93; PMID:18790769; http://dx.doi.org/10.1158/1535-7163.MCT-08-0438

13. Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell
apoptosis and tumor regression. Cancer Res 2001; 61:7255-63; PMID:11585763.

14. Camandola S, Mattson MP. Pro-apoptotic action of PAR-4 involves inhibition of NF-kappaB activity and suppression of BCL-2 expression. J Neurosci Res 2000; 61:134-9; PMID:10878855; http://dx.doi.org/10.1002/1097-4574(20000715)61:1%3c134::AID-JNR3%3e3.0.CO;2-P.

15. Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R, Lopez-Berestein G. Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 2003; 278:19995-20005; PMID:12644474; http://dx.doi.org/10.1074/jbc.M20586200.

16. Chendil D, Das A, Dey S, Mohiuddin M, Ahmed MM. Par-4, a pro-apoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther 2002; 1:152-60; PMID:12170775; http://dx.doi.org/10.4161/cbi.61.

17. Qiu G, Ahmed M, Sells SF, Mohiuddin M, Weinstein MH, Rangnekar VM. Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 1999; 18:6239-41; PMID:9989812; http://dx.doi.org/10.1038/sj.onc.1202434.

18. Bergmann M, Kukoc-Zivojnov N, Chow KU, Trephol B, Hoelzer D, Weidmann E, Mitrou PS, Boeherl S. Prostate apoptosis response gene-4 sensitizes neoplastic lymphocytes to CD95-induced apoptosis. Annals of hematology 2004; 83:646-53; PMID:15316756; http://dx.doi.org/10.1007/s00277-004-0922-3.

19. Lee TJ, Jang JH, Noh HJ, Park EJ, Choi KS, Kwon TK. Overexpression of Par-4 sensitzes TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling pathways in renal cancer cells. J Cell Biochem 2010; 109:885-95; PMID:20127709; http://dx.doi.org/10.1002/jcb.22504.

20. Thayyullathil F, Rahman A, Pallichankandy S, Patel M, Galadari S. Reduction of TRIM21/Ro52 predicts poor prognosis in diffuse large B cell lymphoma patients with and without rheumatic disease. J Intern Med 2015; 278:323-32; PMID:25880119; http://dx.doi.org/10.1111/joim.12375.

21. Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun 2012; 39:77-82; PMID:22402340; http://dx.doi.org/10.1016/j.jaut.2012.01.014.

22. Chaudhry P, Singh M, Parent S, Asselin E. Prostate apoptosis response 4 (Par-4), a novel substrate of caspase-3 during apoptosis activation. Mol Cell Biol 2012; 32:8286-39; PMID:22184067; http://dx.doi.org/10.1128/MCB.06321-11.

23. Tan J, You Y, Xu T, Yu P, Wu D, Deng H, Zhang Y, Bie P. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT. Toxicol Lett 2013; 224:7-15; PMID:24144893; http://dx.doi.org/10.1016/j.toxlet.2013.10.005.

24. Cook J, Krishnan S, Ananth S, Sells SF, Shi Y, Walther MM, Linehan WM, Sukhatme VP, Weinstein MH, Rangnekar VM. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 1999; 18:1205-8; PMID:10022126; http://dx.doi.org/10.1038/sj.onc.1202416.

25. Joshi J, Fernandez-Marcos PJ, Galvez A, Amancy R, Linares JF, Duran A, Pathrose P, Leitges M, Camanero M, Collado M, et al. Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J 2008; 27:2181-93; PMID:18650932; http://dx.doi.org/10.1038/emboj.2008.149.

26. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, Tendero MJ, Rodriguez-Pinilla SM, Garcia-Cao I, Hardisson D, Diaz-Meco MT, Moscat J, Serrano M, et al. Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 2007; 67:1927-34; PMID:17332319; http://dx.doi.org/10.1158/0008-5472.CAN-06-2687.

27. Lee TJ, Lee JT, Kim SH, Choi YH, Song KS, Park JW, Kwon TK. Overexpression of Par-4 enhances thapsigargin-induced apoptosis via down-regulation of XIAP and inactivation of Akt in human renal cancer cells. J Cell Biochem 2008; 103:358-68; PMID:18041764; http://dx.doi.org/10.1002/jcb.21642.

28. Brasseur K, Fabi F, Adam P, Parent S, Lessard E, Asselin E. Post-translational regulation of the cleaved fragment of Par-4 in ovarian and endometrial cancer cells. Oncotarget 2016; 7;13:15164-7; PMID:27269662; http://dx.doi.org/10.18632/oncotarget.8973.

29. El-Guendy N, Zhao Y, Gurmurthy S, Burikhanov R, Rangnekar VM. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 2003; 23:5516-25; PMID:12897127; http://dx.doi.org/10.1128/MCB.23.16.5516-5525.2003.

30. Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol 2016; 7;7:1103-24; PMID:26686018; http://dx.doi.org/10.1007/s00280-016-2976-z.

31. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9;6:967-5; PMID:22930834; http://dx.doi.org/10.1038/nmeth.2089.